GSK announced partial success in its late-stage ovarian cancer trials, where their drug Jemperli showed improved outcomes ...

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...

Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...

The First-Engot-OV44 phase III trial evaluated niraparib, sold under the brand name Zejula, and dostarlimab, sold under the brand name, Jemperli. The London-based pharmaceuticals firm said the trial ...

GSK's combined drugs Jemperli and Zejula met its primary goal of progression-free survival in patients with first line advanced ovarian cancer in a late-stage trial.